Driving R&D with a clinical focus on genetic diseases

Driving R&D with a clinical focus on genetic diseases

Employing breakthrough molecular strategies with a focus on neurodegenerative diseases.

Employing breakthrough molecular strategies with a focus on neurodegenerative diseases.

Explore

Partnerships

Driving R&D with a clinical focus on genetic diseases

Employing breakthrough molecular strategies with a focus on neurodegenerative diseases.


At Vera, every treatment starts with a story

At Vera Pharmaceutical, we harness the power of antisense oligonucleotides to confront neurodegenerative diseases head-on. Our approach uses advanced antisense technology to directly target the genes responsible for neurodegenerative disorders, providing real options for patients and their families.

Streamlined Paths, Real Results

Our mission is simple: accelerate the transition from genetic discovery to personalised treatment, bringing relief and renewed possibilities to patients sooner.

Identify the target

Using data from genome sequencing centers, we pinpoint suitable targets for oligonucleotide approaches.

Using data from genome sequencing centers, we pinpoint suitable targets for oligonucleotide approaches.

Synthesize selected ASO

We execute the synthesis of chosen oligonucleotides to prepare them for further evaluation.

We execute the synthesis of chosen oligonucleotides to prepare them for further evaluation.

Find the efficient oligonucleotides

Find the efficient oligonucleotide

We evaluate performance using assays on cultured cells to identify the most promising candidates.


We evaluate performance using assays on cultured cells to identify the most promising candidates.


Optimized compute, precise predictions

Deploying the power of cloud bioinformatics computing to predict and analyze a precise path to discoveries.

Deploying the power of cloud bioinformatics computing to predict and analyze a precise path to discoveries.

Therapeutic Potential of Antisense Oligonucleotides

Therapeutic Potential of Antisense Oligonucleotides

Antisense oligonucleotides (ASOs) are short, modified sequences designed to bind RNA targets with high specificity, regulating gene expression to treat genetic and neurodegenerative diseases.

Effective ASOs require chemical modifications, including sugar modifications (2′-MOE) for increased binding and stability, and phosphate modifications (phosphorothioate) for improved tissue uptake.

Antisense oligonucleotides (ASOs) are short, modified sequences designed to bind RNA targets with high specificity, regulating gene expression to treat genetic and neurodegenerative diseases.

Effective ASOs require chemical modifications, including sugar modifications (2′-MOE) for increased binding and stability, and phosphate modifications (phosphorothioate) for improved tissue uptake.

Empower Research & Development

Empower Research & Development

Step into our dynamic and accessible biological and chemical labs, crafted specifically to fuel collaborative breakthroughs. Equipped with innovative technologies, our spaces support smoother workflows, shorten development cycles, and stimulate groundbreaking discoveries. Our mission revolves around three key pillars: quick results, shared expertise, and unmatched effectiveness.

Step into our dynamic and accessible biological and chemical labs, crafted specifically to fuel collaborative breakthroughs. Equipped with innovative technologies, our spaces support smoother workflows, shorten development cycles, and stimulate groundbreaking discoveries. Our mission revolves around three key pillars: quick results, shared expertise, and unmatched effectiveness.

At Vera Pharmaceutical, our strength lies in our people. A passionate team of therapeutic researchers, organic chemists and bioinformaticians collaborate closely, turning scientific ideas into groundbreaking solutions.

Contact Us

Have any questions? Just complete the form below, and we'll get back to you quickly.